Obeticholic Acid - CAS 459789-99-2
Catalog number: B0084-463355
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Obeticholic Acid is a potent and selective farnesoid X receptor (FXR) agonist with EC50 of 99 nM. It reduced liver fat and reverted cholestasis in a rat model.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-463355 100 mg $199 In stock
Bulk Inquiry
White Solid
6-ECDCA; 6-Ethylchenodeoxycholic acid; (4R)-4-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
Melting Point:
>98ºC (dec.)
Canonical SMILES:
1.Bile salts in control of lipid metabolism.
Schonewille M1, de Boer JF, Groen AK. Curr Opin Lipidol. 2016 Mar 30. [Epub ahead of print]
PURPOSE OF REVIEW: The view on bile salts has evolved over the years from being regarded as simple detergents that aid intestinal absorption of fat-soluble nutrients to being important hormone-like integrators of metabolism. This review provides an update on the rapidly developing field of interactions between bile salts and lipid metabolism, with a particular emphasis on the underlying mechanisms.
2.Novel Pharmacotherapy Options for NASH.
Ratziu V1. Dig Dis Sci. 2016 May;61(5):1398-405. doi: 10.1007/s10620-016-4128-z. Epub 2016 Mar 22.
While simple to recommend, diet and lifestyle measures as a first-line therapy for nonalcoholic steatohepatitis (NASH) are hardly a model of successful therapy, as most clinicians can testify. They can be complex to implement, hard to sustain, and of limited efficacy in advanced stages of the disease. The need for specific pharmacotherapy is now acknowledged by practitioners, the pharmaceutical industry, and regulators and is largely expected by patients. The result is a clear move away from products developed second hand for NASH (such as pioglitazone or metformin) or from generic, non-specific hepatoprotectors (such as pentoxifylline, ursodeoxycholic acid, or antioxidants) toward molecules developed and tested specifically for NASH that aim to correct one or several of the pathways of liver injury in this disease. The two most advanced molecules, obeticholic acid and elafibranor, have shown encouraging data on improving hepatic histology.
3.Therapeutic advances for primary biliary cholangitis: the old and the new.
Wang L1, Zhang FC, Zhang X. Eur J Gastroenterol Hepatol. 2016 Jun;28(6):615-21. doi: 10.1097/MEG.0000000000000591.
Primary biliary cholangitis (PBC, primary biliary cirrhosis) is an autoimmune cholestatic liver disease characterized by chronic nonsuppurative destructive cholangitis and the presence of serum antimitochondrial antibodies. Ursodeoxycholic acid is the only drug approved by the US Food and Drug Administration to treat PBC. However, one-third of patients show incomplete responses to ursodeoxycholic acid and a poor prognosis. A number of old and new medications have been used in these patients, such as fibrates, glucocorticoids, immunosuppressants, obeticholic acid, mesenchymal stem cells, biological agents (anti-interleukin-12, cytotoxic T-lymphocyte antigen 4 immunoglobulin, anti-CD20), and antifibrotic drugs. This article reviews the therapeutic advances of these old and new medications in patients with PBC.
4.Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
Ho PP1, Steinman L2. Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):1600-5. doi: 10.1073/pnas.1524890113. Epub 2016 Jan 25.
Bile acids are ligands for the nuclear hormone receptor, farnesoid X receptor (FXR). The bile acid-FXR interaction regulates bile acid synthesis, transport, and cholesterol metabolism. Recently, bile acid-FXR regulation has been reported to play an integral role in both hepatic and intestinal inflammation, and in atherosclerosis. In this study, we found that FXR knockout mice had more disease severity in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). Obeticholic acid (6α-ethyl-chenodeoxycholic acid, 6-ECDCA), a synthetic FXR agonist, is an orally available drug that is currently in clinical trials for the treatment of inflammatory diseases such as alcoholic hepatitis, nonalcoholic steatohepatitis, and primary biliary cirrhosis. When we treated mice exhibiting established EAE with 6-ECDCA, or the natural FXR ligand chenodeoxycholic acid (CDCA), clinical disease was ameliorated by (i) suppressing lymphocyte activation and proinflammatory cytokine production; (ii) reducing CD4(+) T cells and CD19(+) B cell populations and their expression of negative checkpoint regulators programmed cell death protein 1 (PD1), programmed death-ligand 1 (PD-L1), and B and T lymphocyte attenuator (BTLA); (iii) increasing CD8(+) T cells and PD1, PDl-1, and BTLA expression; and (iv) reducing VLA-4 expression in both the T- and B-cell populations.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related FXR Products

CAS 1000403-03-1 INT-767

(CAS: 1000403-03-1)

INT-767, a steride compound, has been found to be a inhibitor of FXR and TGF5 and could have probable effect against some liver and metabolic diseases. It was j...

(CAS: 1268244-85-4)

PX-102, also known as PX-20606, is a farnesoid X-activated receptor (FXR) agonist. PX-102 is indicated to be active in lowering plasma cholesterol, and ameliora...

(CAS: 1103500-20-4)

LY2562175 is a potent and selective FXR agonist in vitro. It has robust lipid modulating properties, lowering LDL and triglycerides while raising HDL in preclin...

PX 102
(CAS: 1268245-19-7)

PX102 is a Farnesoid X-activated Receptor (FXR) agonist originated by Phenex Pharmaceuticals. PX102 demonstrated potent plasma cholesterol-lowering activity tha...

CAS 1612191-86-2 BAR502

(CAS: 1612191-86-2)

BAR502 is a dual FXR and GPBAR1 agonist (IC50= 2 μM and 0.4 μM for FXR and GPBAR1, respectively).

CAS 1383816-29-2 Tropifexor

(CAS: 1383816-29-2)

Tropifexor is a novel highly potent agonist of farnesoid X receptor (FXR), which regulates bile acid metabolism and signaling. FXR activated by Tropifexor can i...

CAS 1198085-23-2 PX 20350

PX 20350
(CAS: 1198085-23-2)

PX 20350 is a farnesoid X receptor (FXR) agonist with enhanced affinity and efficacy (12 nM and 109% (compared to GW 4064)) in FXR FRET assay and full length FX...

CAS 574013-66-4 Fexaramine

(CAS: 574013-66-4)

Fexaramine is a small molecule farnesoid X receptor agonist with 100-fold increased affinity relative to natural compounds.

CAS 474-25-9 Chenodeoxycholic Acid

Chenodeoxycholic Acid
(CAS: 474-25-9)

Chenodeoxycholic Acid is a naturally occurring human bile acid.Chenodeoxycholic acid has been used as medical therapy to dissolve gallstones.

CAS 278779-30-9 GW4064

(CAS: 278779-30-9)

GW4064 is a selective non-steroidal agonist of farnesoid X receptor (FXR) with EC50 value of 15 nM.

CAS 459789-99-2 Obeticholic Acid

Obeticholic Acid
(CAS: 459789-99-2)

Obeticholic Acid is a potent and selective farnesoid X receptor (FXR) agonist with EC50 of 99 nM. It reduced liver fat and reverted cholestasis in a rat model.

(CAS: 1609564-75-1)

DY-268, a pyrazol carboamide derivative, has been found to be a FXR antagonist that could be significant in studies of the biological activities of FXR. IC50: 7...


EP-024297 is a novel agonist of farnesoid X receptor (FXR). Study in Chinese hamster ovary cells showed that it is 20000-fold more potent than obeticholic acid ...

CAS 39025-23-5 Z-Guggulsterone

(CAS: 39025-23-5)

Z-Guggulsterone is a broad spectrum steroid receptor ligand that acts as a mineralocorticoid, progesterone and glucocorticoid receptor antagonist (Ki = 37, 224 ...

CAS 629664-81-9 Turofexorate Isopropyl

Turofexorate Isopropyl
(CAS: 629664-81-9)

Turofexorate Isopropyl is a highly potent, selective, and orally active farnesoid X receptor (FXR) agonist.

Chemical Structure

CAS 459789-99-2 Obeticholic Acid

Quick Inquiry

Verification code

Featured Items